270 related articles for article (PubMed ID: 20606648)
1. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.
Chen Y; Zhu X; Zhang X; Liu B; Huang L
Mol Ther; 2010 Sep; 18(9):1650-6. PubMed ID: 20606648
[TBL] [Abstract][Full Text] [Related]
2. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.
Wiggins JF; Ruffino L; Kelnar K; Omotola M; Patrawala L; Brown D; Bader AG
Cancer Res; 2010 Jul; 70(14):5923-30. PubMed ID: 20570894
[TBL] [Abstract][Full Text] [Related]
3. Endogenous microRNA triggered enzyme-free DNA logic self-assembly for amplified bioimaging and enhanced gene therapy via in situ generation of siRNAs.
Jiang Q; Yue S; Yu K; Tian T; Zhang J; Chu H; Cui Z; Bi S
J Nanobiotechnology; 2021 Sep; 19(1):288. PubMed ID: 34565382
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous cytosolic delivery of a chemotherapeutic and siRNA using nanoparticle-stabilized nanocapsules.
Hardie J; Jiang Y; Tetrault ER; Ghazi PC; Tonga GY; Farkas ME; Rotello VM
Nanotechnology; 2016 Sep; 27(37):374001. PubMed ID: 27505356
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeted lung cancer therapy
Han Y; Yang Y; Sun Q; Li B; Yue C; Liu Y; de la Fuente JM; Cui D
Cancer Biol Med; 2021 Aug; 19(7):1047-60. PubMed ID: 34427999
[TBL] [Abstract][Full Text] [Related]
6. Progress in microRNA delivery.
Zhang Y; Wang Z; Gemeinhart RA
J Control Release; 2013 Dec; 172(3):962-74. PubMed ID: 24075926
[TBL] [Abstract][Full Text] [Related]
7. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.
Trang P; Wiggins JF; Daige CL; Cho C; Omotola M; Brown D; Weidhaas JB; Bader AG; Slack FJ
Mol Ther; 2011 Jun; 19(6):1116-22. PubMed ID: 21427705
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics.
Muthiah M; Park IK; Cho CS
Expert Opin Drug Deliv; 2013 Sep; 10(9):1259-73. PubMed ID: 23826971
[TBL] [Abstract][Full Text] [Related]
9. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma.
Chiou GY; Cherng JY; Hsu HS; Wang ML; Tsai CM; Lu KH; Chien Y; Hung SC; Chen YW; Wong CI; Tseng LM; Huang PI; Yu CC; Hsu WH; Chiou SH
J Control Release; 2012 Apr; 159(2):240-50. PubMed ID: 22285547
[TBL] [Abstract][Full Text] [Related]
10. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy.
Wang S; Cao M; Deng X; Xiao X; Yin Z; Hu Q; Zhou Z; Zhang F; Zhang R; Wu Y; Sheng W; Zeng Y
Adv Healthc Mater; 2015 Jan; 4(2):281-90. PubMed ID: 25044638
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma.
Babar IA; Cheng CJ; Booth CJ; Liang X; Weidhaas JB; Saltzman WM; Slack FJ
Proc Natl Acad Sci U S A; 2012 Jun; 109(26):E1695-704. PubMed ID: 22685206
[TBL] [Abstract][Full Text] [Related]
13. Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing.
Shi J; Xu Y; Xu X; Zhu X; Pridgen E; Wu J; Votruba AR; Swami A; Zetter BR; Farokhzad OC
Nanomedicine; 2014 Jul; 10(5):897-900. PubMed ID: 24650883
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs and other non-coding RNAs as targets for anticancer drug development.
Ling H; Fabbri M; Calin GA
Nat Rev Drug Discov; 2013 Nov; 12(11):847-65. PubMed ID: 24172333
[TBL] [Abstract][Full Text] [Related]
15. Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology.
McKiernan PJ; Cunningham O; Greene CM; Cryan SA
Int J Nanomedicine; 2013; 8():3907-15. PubMed ID: 24143095
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
Beg MS; Brenner AJ; Sachdev J; Borad M; Kang YK; Stoudemire J; Smith S; Bader AG; Kim S; Hong DS
Invest New Drugs; 2017 Apr; 35(2):180-188. PubMed ID: 27917453
[TBL] [Abstract][Full Text] [Related]
17. Preparation and Optimization of MiR-375 Nano-Vector Using Two Novel Chitosan-Coated Nano-Structured Lipid Carriers as Gene Therapy for Hepatocellular Carcinoma.
Soliman B; Wen MM; Kandil E; El-Agamy B; Gamal-Eldeen AM; ElHefnawi M
Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675155
[TBL] [Abstract][Full Text] [Related]
18. Nanotechnology-based delivery systems to overcome drug resistance in cancer.
Patel H; Li J; Bo L; Mehta R; Ashby CR; Wang S; Cai W; Chen ZS
Med Rev (2021); 2024 Feb; 4(1):5-30. PubMed ID: 38515777
[TBL] [Abstract][Full Text] [Related]
19. miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities.
Huang W; Paul D; Calin GA; Bayraktar R
Cells; 2023 Dec; 13(1):. PubMed ID: 38201290
[TBL] [Abstract][Full Text] [Related]
20. Protein-based nanoparticles for therapeutic nucleic acid delivery.
Eweje F; Walsh ML; Ahmad K; Ibrahim V; Alrefai A; Chen J; Chaikof EL
Biomaterials; 2024 Mar; 305():122464. PubMed ID: 38181574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
